Objective-Calcific aortic valve disease is the most prevalent valvulopathy in Western countries. An unanticipated pathogenetic clue involving IFN (interferon) was disclosed by the finding of constitutive type I IFN activity associated with aortic valve calcification in children with the atypical Singleton-Merten syndrome. On this basis, the role of type I IFN on inflammation and calcification in human aortic valve interstitial cells (AVIC) was examined. Approach and Results-IFN-α was weakly proinflammatory but potentiated lipopolysaccharide-mediated activation of NF (nuclear factor)-κB and the ensuing induction of proinflammatory molecules in human AVIC. Stimulation with IFN-α and in combination with lipopolysaccharide promoted osteoblast-like differentiation characterized by increased osteoblastic gene expression, BMP (bone morphogenetic protein)-2 secretion, and ectopic phosphatase activity. Sex differences were observed. Likewise, IFN-α treatment of human AVICs in osteogenic medium resulted in increased formation of calcific nodules. Strikingly, IFN-α-mediated calcification was significantly higher in AVICs from males, and was blocked by tofacitinib, a JAK (Janus kinase) inhibitor, and by a BMP antagonist. A female-specific protective mechanism involving the activation of PI3K-Akt (protein kinase B) pathways and cell survival was disclosed. Females exhibited higher levels of BCL2 in valve cells and tissues and lower annexin V staining on cell stimulation. Conclusions-IFN-α acts as a proinflammatory and pro-osteogenic cytokine in AVICs, its effects being potentiated by lipopolysaccharide. Results also uncovered sex differences with lower responses in female AVICs and sex-specific mechanisms involving apoptosis. Data point to JAK/STAT (signal transducer and activator of transcription) system as a potential therapeutic target for calcific aortic valve disease. Visual Overview-An online visual overview is available for this article.
C alcific aortic valve disease (CAVD), the most prevalent valvulopathy in the Western world, is characterized by progressive fibrocalcific valve thickening and ventricular function impairment. Surgical valve replacement and transcatheter valve implantation are the only therapies currently available. [1] [2] [3] [4] Increasing evidence points to a triggering of CAVD development by inflammation, with a crucial role on calcification in the early stages of the disease (reviewed 3, 5, 6 ). In this line, TLR (Toll-like receptors) have been associated with inflammatory and osteogenic responses in human aortic valve interstitial cells (AVIC). [7] [8] [9] [10] [11] Type I interferons (IFN-α, β, and others) are pluripotent cytokines secreted in response to viral infections by most cell types. [12] [13] [14] All subtypes are recognized by a receptor composed of 2 subunits, IFNAR (IFN-α/β receptor)-1 and 2, which signals through JAK (Janus kinases) and STAT (signal transducer and activator of transcription). [12] [13] [14] IFN immunoregulatory functions include cell proliferation and differentiation and anti-inflammatory effects, although some aberrant function has been associated with chronic inflammation and autoimmunity. [12] [13] [14] Strikingly, human mutations leading to constitutive type I IFN-activity have been recently associated with calcifications in the aortic valve and the aorta of children with the atypical Singleton-Merten syndrome, a rare autosomal dominant disorder. 15, 16 In the vascular system IFN-α acts as an inflammatory amplifier by upregulating TLR4 expression and increasing some cytokines involved in plaque destabilization. 17 Moreover, IFN-induced cytokine expression is upregulated in human stenotic aortic valves. 18 Additionally, human AVIC secrete type I IFN as well as IFN-related chemokines on activation of TLR3, a receptor involved in recognition of viral particles. 10 In this study, we explored the role of IFN-α in AVICs isolated from control and stenotic aortic valves by studying: (1) its effects on inflammation and osteogenesis and (2) its modulation of TLR signaling.
Human Samples
The study included 23 explanted tricuspid aortic valves from transplant recipients with valve disease excluded by echocardiography (control valves, 16 males/7 females). Stenotic valves included explanted heart valves from 22 patients with CAVD (stenotic valves, 11 males/11 females). European guidelines for diagnosis and indications for valve replacement and heart transplantation were followed. The study complies with the Helsinki Declaration and was approved by the Review Board and Ethics Committee of the Hospital Clínico Universitario de Valladolid (protocol number PI 15-263). All patients gave written informed consent before surgery. Clinical characteristics of patients used for the study are summarized in Table I in the onlineonly Data Supplement. No significant differences in age, race, characteristics, and comorbidities were observed between groups.
Isolation of Valve Interstitial Cells
Interstitial cells were isolated and cultured in M199 medium supplemented with antibiotic-antimycotic agents and 10% fetal bovine serum (FBS) as described. 8, 10 The interstitial cells studied were grouped into the ones isolated from aortic control valves of male (male AVIC) and female (female AVIC) donors, and the ones isolated from aortic stenotic valves of male (stenotic male AVIC) and female (stenotic female AVIC) donors. Most cells stained positively for α-SMA (α-smooth muscle actin), consistent with a myofibroblast phenotype. No apparent morphological differences between sexes were observed. Also, no differences in α-SMA staining between male and female AVICs were observed in basal conditions.
Protocol for Cell Activation
Cells were activated in M199 (Corning, number 10-060-CVR) supplemented with 2% FBS (Hyclone, number SV30160.03) for the indicated times. Stimuli included recombinant human IFN-α (specific activity ≥1.8×10 8 U/mg, Peprotech), and lipopolysaccharide from Escherichia coli O111B4 (Sigma-Aldrich, number L2630), which was previously boiled to eliminate protein contaminants. Other TLR ligands like Pam 2 CSK4 (number tlrl-pm2s-1), flagellin (number tlrlepstfla-5), polyinosinic-polycytidylic acid (poly (I:C)) (number tlrlpic), and imiquimod (number tlrl-imq) were from InvivoGen. Other stimuli include TGF (transforming growth factor)-β (Peprotech Inc, number 100-21) and TNF (tumor necrosis factor)-α (Cell Biolabs, number 12105). In pharmacological studies, cells were pretreated for at least 30 minutes with inhibitors of signaling cascades such as the p38 MAPK (mitogen-activated protein kinases) inhibitor SB203580 (Calbiochem, number 559389), ERK (extracellular signal-regulated kinase) activation inhibitor PD98059 (Tocris, number 1213), JNK (c-Jun N-terminal kinase) inhibitor SP600125 (Sigma-Aldrich, number S5567), the JAK inhibitors ruxolitinib (InvivoGen, number INCB018424) and tofacitinib (InvivoGen, number CP-690550), PI3K inhibitor LY294002 (Invitrogen, number PHZ1144), NF (nuclear factor)-κB inhibitor SN50 (Calbiochem, number 481480), TLR4 signaling antagonist CAY10614 (Cayman Chem, number 13615), and BMP (bone morphogenetic protein) antagonist noggin (Invitrogen, number PHC1506). Protein content of cell lysates was evaluated by the bicinchoninic acid (BCA) assay (Pierce, number 23227).
Immunoblotting for the Detection of Proinflammatory and Pro-Osteogenic Molecules
Cytoplasmic and nuclear extracts were obtained using a nuclear extract kit (Active Motif, number 40010). Whole cell lysates containing 25 μg protein were analyzed by Western blot as described. 10, 11 Antibody details are in the online Major Resource Table in the online-only Data Supplement. To study proinflammatory molecules and routes, we used antibodies against human ICAM (intercellular adhesion molecule)-1 and VCAM (vascular cell adhesion molecule)-1 from Santa Cruz Biotech Inc. The phosphorylated forms of NF-κB-p65, of the MAP kinases ERK and JNK, of Akt (protein kinase B), of STAT1 and STAT3 (Tyr705) were from Cell Signaling, and p-p38 antibody was from Sigma-Aldrich. To analyze osteogenic molecules, an antibody against Runx2 (Runt-related transcription factor-2) from Cell Signaling was used. An anti-β-tubulin antibody from Sigma-Aldrich was used as loading control. To analyze cytosolic and nuclear extracts, NF-κB-p65 and STAT1 antibodies from Cell Signaling, and an anti-histone H3 antibody-nuclear loading control from Abcam were used. Secondary antibodies included goat-anti-mouse IgG from Bio-Rad, and polyclonal goat anti-rabbit Igs from Dako. Proteins were visualized using Pierce ECL Western blotting substrate (ThermoScientific, number 32106).
Densitometric analysis was performed using Quantity One analysis software (Bio-Rad), and data are expressed as arbitrary units (a.u.) normalized to β-tubulin and to basal conditions.
Reverse-Transcriptase Polymerase Chain Reaction
First, total RNA was isolated from interstitial valve cells and from human valve tissue by using TRI reagent (Invitrogen, number AM9738) following the manufacturer's protocol. Valve tissue was homogenized using an Omni tissue homogenizer (Omni International). RNA was later analyzed by reverse transcriptase quantitative PCR. First-strand cDNA (1.5 μg) were synthesized from RNA by the reverse transcription reaction (Invitrogen, number 28025-013), and 20 ng were later amplified by PCR using SYBRgreen (Kapa Biosystems, number KK4610) with the corresponding primers. AKT1: Forward 5′-AGCGACGTGGCTATTGTGAAG-3′; reverse 5′-GCCATCATTCTTGAGGAGGAAGT-3′. BCL2: Forward 5′-GG TGGGGTCATGTGTGTGG-3′; reverse 5′-CGGTTCAGGTACTCA GTCATCC-3′. BSP2: Forward 5′-CCCCACCTTTTGGGAAAA CCA-3′; reverse 5′-TCCCCGTTCTCACTTTCATAGAT-3′. GAPDH: Forward 5′-TGCCAAATATGATGACATCAAGAA-3′; reverse 5′-GGAGTGGGTGTCGCTGTTG-3′ 
α-SMA Detection by Immunocytochemistry

AVIC (10-12×10
3 ) seeded on uncoated coverslips were activated with ligands for 48 hours and then fixed and permeabilized with methanol for 6 minutes at −20°C. Nonspecific binding was blocked by incubation with PBS supplemented with 5% BSA. Next, cells were incubated with a mouse anti-human α-SMA antibody (Santa Cruz Biotech Inc, number sc3225, 1.4 ng/mL) for 1 hour, and a rat anti-mouse IgG (H+L) (FITC) polyclonal antibody (eBioscience, Inc, number 11-4011-85, 5 μg/mL) for 1 hour. Before mounting, cells were incubated with DAPI (4′, 6-diamidino-2-phenylindole, dihydrochloride; Sigma-Aldrich, number D9564) for 5 minutes to stain nuclei. Images were obtained with a fluorescence microscope coupled to a digital camera (Nikon Eclipse 80i). The total corrected cellular fluorescence=integrated density−(area of selected cell×mean fluorescence of background readings) was calculated using ImageJ software (National Institutes of Health).
In Vitro Calcification Assay
Assays were performed using a high phosphate concentration as described. 20 Cells were incubated for 17 to 21 days in conditioned medium, M199 supplemented with 3 mmol/L inorganic phosphate and 1% FBS, changing medium with stimuli every 3 to 4 days. Then, mineralization was evaluated by 2 independent methods using different cells and technical replicates.
Calcification Nodule Detection by Alizarin Red Staining
To visualize the calcium-based mineralization, cells were fixed with 4% p-formaldehyde for 15 minutes and stained with 1.4% alizarin red (Sigma-Aldrich, number A5533) for 15 minutes. After removal of nonspecific staining by washing with PBS, cells were visualized using a phase-contrast microscope coupled to a digital camera (Nikon Eclipse TS100). Alizarin red staining quantification was performed by a method previously described by Gregory et al, 21 consisting of an acetic acid extraction and later neutralization with ammonium hydroxide followed by colorimetric detection at 450 nm.
Calcium Deposition Quantification
Cells were washed with PBS and decalcified with 0.6 N HCl at 4°C for 24 hours. Then, supernatants were collected and used to quantify calcium with the Quantichrom Calcium assay kit (Bioassay Systems, number DICA500). Cells were collected in lysis buffer (0.1 N NaOH and 0.1% SDS) for protein extraction and quantification. Data were normalized to total cell protein content.
Ectopic Phosphatase Activity
Cells were activated with the indicated ligands for 21 days in M199 supplemented with 1% FBS, and ectopic phosphatase activity was assayed using a colorimetric method. Activated cells were incubated with phenol-red-free M199 supplemented with 10 mmol/L p-nitrophenyl phosphate (Sigma-Aldrich, number N4645) at 37°C for 12 hours. The formation of the product was assessed by measuring absorbance at 405 nm. Activity was calculated using a molar extinction coefficient of 18.75 mmol/L −1 ×cm −1 . Data were normalized to total cell protein content.
Proliferation Assays
Cells were seeded at 2500 cells per well in 96 well plates and allowed to attach overnight. Cells were then activated for 12 days in phenolred free medium. Medium with stimuli were replaced every 3 days. At day 12, medium was changed and 5 mg/mL MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Sigma-Aldrich, number M5655) were added to each well to reach a final concentration of 1 mg/mL). Cells were then incubated at 37°C for 4 hours, followed by formazan extraction with SDS 10% in HCl 0.01 N at 37°C for 4 hours. The product was quantified by measuring the absorbance at 570 nm and at 630 nm (background). Data were expressed as absorbance A 570 -A 630 .
Apoptosis and Necrosis Assays by Flow Cytometry
Approximately 100 000 cells were activated with the indicated ligands for 7 days in M199 supplemented with 3 mmol/L inorganic phosphate and 1% FBS. Apoptotic assay was performed by cell staining followed by flow cytometry analysis. Briefly, AVICs were detached with StemPro Accutase (Gibco, number 11599686), centrifuged, and resuspended in Annexin V Binding Buffer (140 mmol/L NaCl, 2.5 mmol/L CaCl 2 , 10 mmol/L HEPES pH 7.4). Following manufacturer's protocol, cells were stained with FITC-ApoScreen annexin V (Southern Biotech, number 10040-02) for 15 minutes on ice and with ApoScreen propidium iodide (Southern Biotech, number 10044-01), and then subjected to analysis by a Gallios Flow Cytometer (Beckman Coulter, Inc). Data were plotted and analyzed using Kaluza Flow Analysis Software (Beckman Coulter, Inc). Data were expressed as % of annexin V-positive cells (B1+B2 shown in plot from Figure 6F ).
Statistical Analysis
All values were expressed as mean±SEM. P refers to the P-adjusted value. Repeated measures 1-way and 2-way ANOVA analyses were performed. When data did not follow normal distribution nor had equal variances, log-transformation was applied previous to analysis. When P<0.05 for interaction between factors (sex/treatment), post hoc analysis applying corrections for multiple comparison by controlling the false discovery rate using the Benjamini-Hochberg procedure was performed. Patient characteristics were analyzed as indicated in Table I in the online-only Data Supplement using the Student t test for categorical variables and the Fisher exact (frequency under 5) or χ 2 tests for continuous variables. Statistical analysis was performed using GraphPad Prism 7 software.
Results
IFN-α Activates Several Signaling Routes and Cooperates With TLR Ligands to Activate NF-κB in Control AVIC
To investigate the effect of IFN-α, we first analyzed NF-κB activation. Western blot revealed that IFN-α phosphorylated NF-κB-p65 at 24 hours and further potentiated lipopolysaccharide response ( Figure 1A ). The effect was dose-dependent and maximal at 100 ng/mL of IFN-α, a concentration used throughout the study. At early times, IFN-α also activated the canonical type I IFN-receptor signaling, that is, STAT1/3, Akt, and MAPK ( Figure 1B ; Figure I in the online-only Data Supplement). Moreover, NF-κB-p65 and STAT1 activation were further demonstrated by their nuclear translocation on IFN-α+lipopolysaccharide treatment, an effect blocked by the JAK inhibitor ruxolitinib ( Figure 1C ). Interestingly, crosstalk on NF-κB-p65 phosphorylation seems to be specific of TLR2-4 ligands ( Figure 1D ), which are known to promote inflammation and calcification in human AVIC.
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IFN-α Is Weakly Proinflammatory but Enhances Lipopolysaccharide-Mediated Responses: Sex Differences on Cytokine Secretion
Next, we analyzed NF-κB-regulated inflammatory molecules. On the one hand, we observed cooperation between IFN-α and lipopolysaccharide on the induction of ICAM-1 and VCAM-1, and prostaglandin E 2 secretion (Figure 2A and  2B) . On the other hand, data disclosed marked sex differences on IL-6 and IL-8 secretion, with lower crosstalk effect in AVICs from females ( Figure 2C ). To note, TNF-α, a proosteogenic cytokine in vascular cells, 22 
IFN-α Drives AVIC Differentiation Toward an Osteoblast-Like Phenotype
Because inflammation promotes valvular calcification, 3, 5, 6 we sought to investigate IFN-α effects on AVIC osteogenesis. On 12-day treatment with IFN-α, we observed morphological changes and antiproliferative effects ( Figure 3A and 3B) . Strikingly, a sex-differential gene profile was observed at early times. IFN-α promoted osteoblastic-like differentiation characterized by upregulation of bone sialoprotein 2 (BSP2), 23 
RUNX2
, 24 the osteocyte marker sclerostin (SOST), 25 and tissue-nonspecific alkaline phosphatase (TNAP) 26, 27 genes, and downregulation of the mineralization inhibitor matrix-Gla protein (MGP) gene, 28 only in male AVICs ( Figure 3C and  3D) . Additionally, the secretion of BMP-2 and MMP-1 was induced in male but not in female AVICs on treatment for 24 hours ( Figure 4A and 4B) .
To further investigate the differentiation process, we examined the myofibroblast marker α-SMA and ectopic phosphatase activity at longer times. IFN-α promoted a decrease of α-SMA fibers and phosphatase activity upregulation ( Figure 4C and 4D) , supporting an osteoblastic-like differentiation. Despite sex differences at early times, no differences were observed on long-term treatment. Data argue for an IFN-α-mediated differentiation process that is delayed in female AVICs.
IFN-α Treatment Potentiated by Lipopolysaccharide Leads to Increased Calcification, the Extent Being Greater in Male AVICs
Next, we performed calcification assays in conditioned medium and analyzed mineralization by alizarin red staining and calcium deposition measurements. IFN-α-promoted calcific nodule formation that was further potentiated by lipopolysaccharide ( Figure 5A and 5B). Remarkably, female AVIC showed significantly lower levels of calcification on stimulation ( Figure 5A and 5B).
JAK/STAT and BMP Are Downstream Effectors of Male-Preferential Calcification
Strikingly, IFN-α-mediated calcification of male AVICs was markedly decreased by tofacitinib ( Figure 5C and 5D) , an oral JAK inhibitor currently used for rheumatoid arthritis treatment. 29 Because BMP-2 secretion on activation is higher in male AVICs (Figure 4A ), we explored the involvement of this route in calcification. We found that IFN-α-mediated calcification of male AVIC was decreased by BMP signaling blockade ( Figure 5E and 5F).
Next, we explored BMP-2 downstream effectors reported in AVICs. 30 Runx2, upregulated by IFN-α at the mRNA level ( Figure 3C ), showed nuclear localization in basal conditions and its protein levels were downregulated on activation with IFN-α ( Figure IIIA and IIIB in the online-only Data Supplement). The unexpected Runx2 downregulation parallels IFN-α-induced osteoblastic differentiation (Figures 3 and 4) . To confirm these results, we tested in parallel the effect of the osteogenic cytokines TNF-α and TGF-β ( Figure IIIB in the online-only Data Supplement). Data suggest different mechanisms of Runx2 regulation in AVIC. As a putative mechanism of Runx2 downregulation, we found that IFN-α-induced upregulation of SMURF1 ( Figure IIIC in the online-only Data Supplement), an E3 ubiquitin ligase that regulates bone formation. 31 Later, we explored alternative transcription factors involved in osteogenesis. The expression of homeobox protein MSX2 gene was only induced on lipopolysaccharide activation ( Figure IIID 
Female Akt Activation and Lower Apoptosis Are Mechanisms Underlying Sex-Differential Responses
Because of the sex variance observed, we first explored intrinsic differences between sexes in valve tissue and cells ( Figure 6A ; Figure IV and Table II in the onlineonly Data Supplement). When analyzing osteogenic and apoptosis-related genes, we found significant higher basal levels of MGP (matrix-Gla protein) in female valves ( Figure IV in the online-only Data Supplement) and of the anti-apoptotic gene B-cell lymphoma (BCL)-2 in valve tissue and AVICs from females ( Figure 6A ). Strikingly, BCL2 levels were only upregulated in male AVICs on IFN-α activation ( Figure 6B ). Data are consistent with reported sex differences in apoptosis in cardiovascular diseases. 32 Because cell death has been associated with dystrophic calcification, 33 we explored cell survival pathways. Strikingly, we found a female-specific phosphorylation of Akt ( Figure 6C ), a kinase recently reported to play a role in AVIC calcification. 34, 35 We further explored the involvement of PI3K/Akt routes in calcification. Remarkably, the PI3K inhibitor LY294002 significantly increased both basal and IFN-α-induced mineralization of female AVICs ( Figure 6D and 6E) . Together, data point to Akt activation as a female-specific and protective mechanism regulating mineralization. Sex differences in cell death on activation with IFN-α+lipopolysaccharide were confirmed using annexin V staining and flow cytometry analysis ( Figure 6F and 6G) . Male AVICs were more prone to apoptosis, which was inhibited by tofacitinib ( Figure 6G ).
Discussion
Our findings highlight the role of IFN-α as an inducer of inflammation and calcification of AVIC and identify a pathogenic mechanism that integrates type I IFN and TLR pathways 
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in a sex-specific manner. Moreover, the use of an inhibitor of the IFN signaling route markedly reduces IFN-α-mediated responses. Human mutations that lead to increased type I IFN activity have been associated with disease (reviewed 16 ), including the early onset of calcification of the aortic valve and the aorta in children with the atypical Singleton-Merten syndrome. 15 In addition to these rare mutations, the valve leaflets might be exposed to type I IFN from different sources (1) release by immune cells to plasma on viral infection; (2) secretion by infiltrating immune cells on activation with cytokines, molecular patterns from pathogens or endogenous danger molecules 12, 13 ; and (3) secretion by resident cells on TLR activation. 10 Therefore, concomitant activation of IFNAR and TLR4 in valve may occur during infections or after tissue damage, including endothelial valve layer injury.
Positive Crosstalk of IFNAR-TLR4 on Inflammation
IFN-α exacerbates the TLR4-mediated proinflammatory phenotype in AVIC, characterized by prostaglandin E 2 and IL-6/8 secretion, and induction of ICAM-1 and VCAM-1, and activation of transcription factors of the NF-κB family, whereas it has a weak proinflammatory activity on its own. Type I IFN secreted after TLR activation may trigger an autocrine loop that amplifies and sustains inflammation in the valve leaflets. Consistent with IFNAR-TLR crosstalk in the vascular system, IFN-α acts as an inflammatory amplifier by upregulating TLR4 expression and increasing the production of cytokines involved in plaque destabilization. 17 Alternative explanation for TLR4 potentiation may include IFN-α-mediated upregulation of MyD88, a mechanism reported in macrophages. 36 In keeping with a recent report highlighting its crucial function as an amplifier of cardiac inflammation after myocardial infarction, 37 the present data expand the emerging role of type I IFN in cardiovascular pathophysiology.
IFNAR-TLR4 crosstalk enhancement of both inflammation and calcification of AVIC supports the notion of inflammation-driven calcification. Because IL-6 is a strong inducer of AVIC osteogenesis, 35 it can be posited that IL-6 secretion may play a key role on calcification potentiation.
IFN-α Induces AVIC Calcification via JAK/BMP Pathways and Apoptosis
Our data unveil IFN-α as an inducer of AVIC calcification via osteoblastic-like differentiation, a mechanism reported to occur in around 15% of resected aortic valves. 33, 38 In nonconditioned medium, the IFN-α-mediated differentiation is characterized by upregulation of osteoblastic markers and ectopic phosphatase activity, α-SMA decrease, and downregulation of the mineralization inhibitor MGP, which is deficient in calcified aortic valves. 28 Our study also discloses an IFN-α-mediated pro-osteogenic effect via a mechanism involving JAK and BMP-2, an osteogenic factor required for aortic valve calcification. 23 ,39 Supporting this hypothesis, IFN-α promoted BMP-2 secretion and mineralization, the latter abrogated by BMP signaling blockade, as well as the activation of ERK and p38 MAPK routes previously associated with calcification in human AVIC. 30, 40 Additionally, our data suggest distinct mechanisms of Runx2 regulation in AVIC: (1) to TNF-α. Our data are consistent with the concept of Runx2 as an early marker upregulated in immature osteoblasts but downregulated in mature osteoblasts, where it is not essential for the maintenance of major bone matrix gene expression. 24 The lack of correlation of Runx2 expression at the mRNA and protein levels suggests a posttranscriptional regulation 41 and stresses the importance of analyzing its protein levels. Other transcription factors with a crucial role on osteogenesis are osterix, 42, 43 and MSX2, but only Osterix transcripts were upregulated upon IFN-α activation, thus suggesting a putative role of this early stage transcription factor.
In high phosphate conditions, IFN-α+lipopolysaccharide mediates mineralization also by promoting cell death, which has been associated to dystrophic calcification of valves. 33 Therefore, BMP-dependent osteogenic mechanism and dystrophic mineralization potentiate calcification under hyperphosphatemia.
The JAK inhibitor tofacitinib, used as a therapy for rheumatoid arthritis, prevents AVIC apoptosis and calcification. The JAK/STAT pathways have been associated with disease, that is, cancer, autoimmune disorders, asthma, etc and targeted for therapeutic intervention (reviewed 44 ). Those pathways are known to sense extracellular signals, including IFNs and cytokines like IL-6, IL-10, and IL-12 p70, thus regulating cell growth and differentiation (reviewed 29, 44 ). Therapeutic intervention on JAK signaling could be a potential treatment for CAVD.
Sex Differences in Response to IFN-α
Emerging evidence points to sex as an important biological variable in CAVD physiopathology. [45] [46] [47] Sex-specific differences in CAVD are supported by recent reports revealing that for the same aortic stenosis severity, women have less calcification. 45 Moreover, calcification via osteoblast differentiation or metaplasia, a heterotopic calcification reported to account for around 15% of resected aortic valves, is more prevalent in males. 33 We have demonstrated that IFN-α alone and in combination with lipopolysaccharide triggered higher inflammation and calcification in male AVICs, which might be pathophysiologically relevant. Dissimilarities on IL-6/ BMP-2/MMP-1 secretion might account for female lower calcification. Additionally, sex differences in osteoblast markers at 24 hours might suggest different kinetics in calcification progression, which seems delayed in female. Moreover, the mineralization inhibitor MGP is upregulated in female valves.
Sex groups were comparable in terms of race, age, characteristics, and comorbidities (Table I in the online-only Data Supplement). Additionally, sex-specific effects are not attributable to differences in cell isolation given the use of the same procedures for all specimens. Male and female AVICs showed heterogeneity but were comparable in basal conditions with no significant differences found in myofibroblast phenotype ( Figure 4C ), cell size/complexity (Figure V in the online-only Data Supplement), and apoptosis ( Figure 6F ).
Female Akt activation accounts for sex differences in calcification progression because its blockade results in increasing mineralization in both basal and activated conditions. Our data are reminiscent of the increased nuclear activity of Akt in females versus males reported in the myocardium. 48 In fact, Akt phosphorylation may account for differences in phosphate metabolism enzymes and lower IL-6 secretion in female AVIC. This hypothesis is supported by Akt-1 gene downregulation in CAVD tissues, and by its reported negative role on AVIC mineralization and apoptosis by modulating the inorganic phosphate transporter SLC20A1. 34, 35 Additionally, Akt has been linked to extracellular matrix deposition in AVIC, 49 which might be relevant to CAVD pathogenesis because more fibrosis has been detected in females. [45] [46] [47] Moreover, Aktmediated survival signals in female might account for differences in cell cycle and apoptosis, an aspect supported by sex differences in BCL2 expression in cells and valvular tissue, and the resistance to IFN-α+lipopolysaccharide mediated apoptosis of female AVICs under hyperphosphatemic conditions. Altogether, our data disclose several pathogenic mechanisms with Akt acting as a negative modulator of osteogenesis and apoptosis in females. This is consistent with male-specific reduction of BCL2 and increase of cell death as a sex-specific mechanism reported in cardiovascular diseases. 32 Because sex differences may have gone unnoticed in studies performed mostly with cells explanted from males, this aspect should be taken into consideration in future studies.
Whether sex differences are based on epigenome alterations by sex hormone exposure would need in-depth investigation. This plausible hypothesis is supported by several evidence suggesting that estrogen receptor-α cooperates with coactivators to epigenetically regulate estrogen-responsive genes such as BCL2 by mechanisms involving PI3K/Akt pathways and histone demethylation. 50 Moreover, testosterone exposure decreased myocardial Akt activation in male heart during cardiac ischemia/reperfusion by mechanisms involving BCL2 and transcriptional repressors. 51 Furthermore, sex-differential regulation of miRNAs has been reported in sex-biased diseases, 52 and miRNA regulation has been described in CAVD. 53 In AVICs, sex differences in Akt activation were observed in response to a stimulus. In this line, type I IFN modulates epigenetic modifications, and its responses can be inhibited by transcriptional repressors downstream targets of Akt.
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Limitations of Our Study
The number of valves from women available for the study was limited, although data were consistent. Additionally, the limitation of our 2-dimensional cellular model stands from the culture on plastic plates that are stiffer than an endogenous matrix leading to a myofibroblast phenotype, termed activated VIC or aVIC, 54 considered an indicator of early disease (reviewed 55 ). Recent data using 3-dimensional gels demonstrate that certain VIC subpopulation may progress to osteogenic nodules through myofibroblast activation previous to an osteoblast-like phenotype. 56 Therefore, our cell model and findings are useful to understand the molecular mechanism underlying the transition from aVIC to osteoblast-like cells, and to elucidate sex differences.
In conclusion, IFN-α alone and in cooperation with lipopolysaccharide promotes inflammation and calcification in AVICs. Female AVIC exhibited lower responses because of mechanisms involving PI3K/Akt/cell survival pathways. Data point to JAK/STAT pathways as putative targets for therapeutic intervention in CAVD.
